# Galderma

Galderma, the pure-play dermatology category leader, delivered record 2025 net sales of $5.21 billion (up 17.7% constant currency) with core EBITDA of $1.21 billion, anchored by the Restylane cross-linked HA filler line.

Source: https://en.bioecon.ru/companies/galderma/
Updated: 2026-06-28

- Country: Switzerland
- Ticker: SIX:GALD

## Technologies

- [Biosynthetic hyaluronic acid](https://en.bioecon.ru/technology/biosynthetic-hyaluronic-acid/)
- [Recombinant botulinum toxin (biosynthetic Botox)](https://en.bioecon.ru/technology/recombinant-botulinum-toxin/)